Healthcare
TriSalus Life Sciences, Inc.(TLSI)
Live Price
Offline$4.08
+4.88% today
1Y Change
-26.47%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $170.00M
- Revenue Growth
- +53.4%
- EPS Growth
- -47.2%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TriSalus Life Sciences, Inc. (TLSI) is a Healthcare stock with a market cap of $170.00M and listed on NASDAQ. The stock last traded around $4.08 and down 26.5% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +53.4%, EPS growth of -47.2%, a dividend yield of 0.0%. What stands out right now is revenue +53.4%, EPS -47.2%, free cash flow +54.0% with operating margin -59.7% and ROIC -112.3%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TLSI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+53.4% vs +7.6% peer median
Operating Margin
Below sector median
-59.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 12, 2026 with an EPS surprise of -106.3% and a revenue surprise of -12.7%.
The operating picture looks softer than before
Revenue is at +53.4% and EPS is at -47.2%, with operating margin around -59.7%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 11, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -22.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | -106.3% | -41.4% | -30.9% | -22.1% |
2026 Mar 5, 2026 | +7.7% | -6.4% | -14.0% | -11.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLSI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TLSI Max Drawdown
-66.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TLSI and SPY.
Company Overview
TriSalus Life Sciences, Inc.
NASDAQ Global Market
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
- Leadership
- Mary T. Szela
- IPO Date
- Feb 8, 2021
- Employees
- 110
- Street Address
- 6272 West 91st Avenue
- Mailing
- Westminster, CO, 80031
- Region
- Westminster, CO, US
- Reporting Currency
- USD
- Investor Line
- 888 321 5212
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.7
- Price/Book
- โ
Growth
- Revenue
- +53.4%
- EPS
- -47.2%
- Free Cash Flow
- +54.0%
Profitability
- Gross Margin
- 84.6%
- Operating Margin
- -59.7%
- Net Margin
- -86.9%
- ROE
- 137.2%
- ROIC
- -112.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.